Richmond, California headquartered Sangamo Therapeutics Inc.'s stock finished Thursday's session 2.93% higher at …
term=healios&rank=1 … Treatment is 1.2B cells and extends the viable treatment window to 36 hours $ATHX Stroke is the leading cause of serious disability in the world. These five stroke survivors have volunteered to share their emotional …
Athersys Inc. (NASDAQ: ATHX) led the bulls on Friday following news of a new partnership and license agreement. The company announced an agreement that will focus on the development and commercialization of novel cell therapy …
Baird analyst Thomas Russo calls the move "a high-risk, potentially high-reward deal even for the biologics space." He rates the stock a hold. Adult stem cells are extracted from human tissue and don't carry the controversy associated …
Navidea Biopharmaceuticals, Inc NAVB announced that it has entered into a definitive agreement to sell its Lymphoseek product to Cardinal Health CAH ... Anika Therapeutics ANIK and Athersys, Inc ATHX. Both of them sport a Zacks …
Richmond, California headquartered Sangamo Therapeutics Inc.'s stock finished Thursday's session 2.93% higher at …
Richmond, California headquartered Sangamo Therapeutics Inc.'s stock finished Thursday's session 2.93% higher at …
Richmond, California headquartered Sangamo Therapeutics Inc.'s stock finished Thursday's session 2.93% higher at …